^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ASP1948

    i
    Other names: ASP1948, PTZ-329, ASP 1948
    Associations

    News

    Trials
    Company:
    Astellas
    Drug class:
    Neuropilin inhibitor
    Related drugs:
    Associations

    News

    Trials
    almost2years
    KEYNOTE-A87: A Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=190, Completed, Astellas Pharma Global Development, Inc. | Phase classification: P1b --> P1
    Phase classification • Combination therapy • Metastases
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    PD-L1 expression • EGFR mutation • PD-L1 overexpression • ALK positive • ALK mutation
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • ASP1948
    almost3years
    KEYNOTE KN-A87: A Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1b, N=190, Completed, Astellas Pharma Global Development, Inc. | Active, not recruiting --> Completed | Trial completion date: Jun 2023 --> Mar 2023 | Trial primary completion date: Jun 2023 --> Mar 2023
    Trial completion • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    PD-L1 expression • EGFR mutation • PD-L1 overexpression • ALK positive • ALK mutation
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • ASP1948
    almost4years
    KEYNOTE KN-A87: A Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1b, N=190, Active, not recruiting, Astellas Pharma Global Development, Inc. | Trial completion date: Apr 2024 --> Jun 2023 | Trial primary completion date: Apr 2024 --> Jun 2023
    Trial completion date • Trial primary completion date • Combination therapy
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    PD-L1 expression • EGFR mutation • PD-L1 overexpression • ALK positive • ALK mutation
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • ASP1948
    4years
    Study of ASP1948, Targeting an Immune Modulatory Receptor, in Japanese Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=9, Completed, Astellas Pharma Inc | Active, not recruiting --> Completed | Trial completion date: Jun 2022 --> Feb 2022 | Trial primary completion date: Jun 2022 --> Feb 2022
    Trial completion • Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • ALK positive • ALK mutation
    |
    ASP1948
    4years
    KEYNOTE KN-A87: A Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1b, N=190, Active, not recruiting, Astellas Pharma Global Development, Inc. | Recruiting --> Active, not recruiting | N=479 --> 190
    Enrollment closed • Enrollment change • Combination therapy
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    PD-L1 expression • EGFR mutation • PD-L1 overexpression • ALK positive • ALK mutation
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • ASP1948
    over4years
    Study of ASP1948, Targeting an Immune Modulatory Receptor, in Japanese Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=9, Active, not recruiting, Astellas Pharma Inc | Trial completion date: Dec 2021 --> Jun 2022 | Trial primary completion date: Dec 2021 --> Jun 2022
    Clinical • Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • ALK positive • ALK mutation
    |
    ASP1948
    5years
    KEYNOTE KN-A87: A Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1b, N=479, Recruiting, Astellas Pharma Global Development, Inc. | Trial completion date: Nov 2023 --> Apr 2024 | Trial primary completion date: Nov 2023 --> Apr 2024
    Clinical • Trial completion date • Trial primary completion date • Combination therapy
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    PD-L1 expression • EGFR mutation • PD-L1 overexpression • ALK positive • ALK mutation
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • ASP1948
    over5years
    Study of ASP1948, Targeting an Immune Modulatory Receptor, in Japanese Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=9, Active, not recruiting, Astellas Pharma Inc | Recruiting --> Active, not recruiting | N=18 --> 9
    Clinical • Enrollment closed • Enrollment change
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • ALK positive • ALK mutation
    |
    ASP1948
    over5years
    KEYNOTE KN-A87: A Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1b, N=479, Recruiting, Astellas Pharma Global Development, Inc. | Trial completion date: Jul 2022 --> Nov 2023 | Trial primary completion date: Jul 2022 --> Nov 2023
    Clinical • Trial completion date • Trial primary completion date • Combination therapy
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    PD-L1 expression • EGFR mutation • PD-L1 overexpression • ALK positive • ALK mutation
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • ASP1948
    almost6years
    Study of ASP1948, Targeting an Immune Modulatory Receptor, in Japanese Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=18, Recruiting, Astellas Pharma Inc | N=12 --> 18
    Clinical • Enrollment change
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • ALK positive • ALK mutation
    |
    ASP1948